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Infantile-Onset Ascending Hereditary Spastic Paralysis Is Associated
with Mutations in the Alsin Gene
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We studied 15 patients, from 10 families, who presented with severe spastic paralysis with an infantile onset and
an ascending progression. Spastic paraplegia began during the first 2 years of life and extended to upper limbs
within the next few years. During the first decade of life, the disease progressed to tetraplegia, anarthria, dysphagia,
and slow eye movements. Overall, the disease was compatible with long survival. Signs of lower motor-neuron
involvement were never observed, whereas motor-evoked potentials and magnetic resonance imaging demonstrated
a primitive, pure degeneration of the upper motor neurons. Genotyping and linkage analyses demonstrated that
this infantile-onset ascending hereditary spastic paralysis (IAHSP) is allelic to the condition previously reported as
juvenile amyotrophic lateral sclerosis at the ALS2 locus on chromosome 2q33-35 (LOD score 6.66 at recombination
fraction 0). We analyzed ALS2, recently found mutated in consanguineous Arabic families presenting either an
ALS2 phenotype or juvenile-onset primary lateral sclerosis (JPLS), as a candidate gene. In 4 of the 10 families, we
found abnormalities: three deletions and one splice-site mutation. All the mutations lead to a truncated alsin protein.
In one case, the mutation affected both the short and the long alsin transcript. In the six remaining families, absence
of cDNA ALS2 mutations suggests either mutations in regulatory ALS2 regions or genetic heterogeneity, as already
reported in JPLS. Alsin mutations are responsible for a primitive, retrograde degeneration of the upper motor
neurons of the pyramidal tracts, leading to a clinical continuum from infantile (IAHSP) to juvenile forms with
(ALS2) or without (JPLS) lower motor-neuron involvement. Further analyses will determinewhether other hereditary
disorders with primitive involvement of the central motor pathways, as pure forms of spastic paraplegia, could be
due to alsin dysfunction.
Introduction
Hereditary spastic paraplegia (HSP) and amyotrophic
lateral sclerosis (ALS) are two groups of disorders char-
acterized mainly by primary degeneration of the central
motor pathways. HSP encompasses a heterogeneous and
expanding group of conditions whose prominent clinical
features are progressive spasticity and weakness of lower
limbs, which may or may not be associated with addi-
tional symptoms (Harding 1981). The genetic hetero-
geneity of pure HSP is known, with an increasing num-
ber of chromosomal localizations (Figlewicz and Bird
1999; Seri et al. 1999; McDermott et al. 2000; Reid et
al. 2000; Vazza et al. 2000). Six genes have been iden-
tified: spastin (MIM 604277; or SPG4, MIM 182601)
(Hazan et al. 1999), paraplegin (MIM 604277; or SPG7,
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MIM 602783) (Casari et al. 1998), L1CAM (MIM
308840; or SPG1, MIM 312900) (Jouet 1994), PLP
(MIM 312080; or SPG2, MIM 312920) (Saugier-Veber
1994), atlastin (MIM 606439; or SPG3A,MIM182600)
(Zhao et al. 2001), and HSP60 (MIM 118190; or
SPG13,MIM 118190) (Hansen 2002). Amyotrophic lat-
eral sclerosis (ALS) is a distinct condition, involving both
upper and lower motor neurons, that results in a pro-
gressive ascending paralysis of lower and upper limbs
and cranial nerves. The classical adult form is sporadic
and rapidly leads to death 2–5 years after onset (Mulder
1986). Rare familial forms with a dominant or recessive
pattern of transmission have been described. Autosomal
dominant forms have been mapped to chromosome
21q21 (ALS1 [MIM 105400]) (Siddique 1991) and
18q21 (ALS6 [MIM 606640]) (Hand et al. 2002). Pa-
tients with ALS1 harbor mutations in the superoxide
dismutase gene (SOD1 [MIM 147450] (Rosen et al.
1993). Families with more rare autosomal recessive in-
heritance have shown linkage to several loci: 2q33
(ALS2 [MIM 205100]), 15q15-21 (ALS5 [MIM
602099]), and 9q34 (ALS4 [MIM 602433]) (Hentati et
al. 1994, 1998; Chance et al. 1998]. Patients from a
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large consanguineous Tunisian family with juvenile-on-
set ALS show linkage to the 2q33-35 locus (ALS2) (Hen-
tati et al. 1994, 1998; Chance et al. 1998).
The term “primary lateral sclerosis” (PLS) has been
used to describe a very uncommon type of selective up-
per motor-neuron involvement, sparing lower motor
neurons. Its relationship with ALS remains controver-
sial (Pringle et al. 1992). Recently, homozygous muta-
tions in a newly identified gene (ALS2 [MIM 606352])
on chromosome 2q33 have been found in the initial
Tunisian family with ALS2 and in three additional con-
sanguineous families from the Arabic peninsula. One
family displays a juvenile-onset ALS2 phenotype, and
two families display a juvenile-onset PLS phenotype
(PLSJ [MIM 606353]; Hadano et al. 2001a; Yang et al.
2001). The ALS2 gene encompasses 34 exons and en-
codes a protein termed “alsin.” Two alternative spliced
variants have been described: the long variant (6394 nt,
1657 aa) and the short variant (2651 nt, 396 aa), the
latter resulting in a premature stop codon after 25 aa
residues in intron 4. It has been proposed that ALS2
mutations might predict the severe PLS phenotype,
when only the long alsin protein is altered, or the even
more severe ALS phenotype, when the short transcript
is also affected. Herein we report genetic analyses of 15
patients from 10 unrelated families who presented a
pure form of slow, progressive, ascending spastic pa-
ralysis with involvement of the lower limbs during in-
fancy (age 1–2 years) and subsequent extension to the
upper limbs and bulbar muscles after 5–10 years of
evolution.
Subjects and Methods
Patients
We studied 15 patients from 10 unrelated families of
different ethnic origins (fig. 1 and table 1). In four fam-
ilies, affected sib pairs suggested a recessive pattern of
transmission (families 362, 408, 279, and 786). In family
362, from Algeria, parents were first cousins. In family
408, both parents were members of the same Libyan
tribe with a strong history of consanguinity; however, a
precise pedigree to identify the degree of consanguinity
between both parents was impossible to obtain. In fam-
ilies 279 and 786, of Italian origin, no consanguinity
was reported. In six families, there was a single affected
child and healthy siblings: one consanguineous family
was from Italy (family 283) and five nonconsanguineous
families were from France (families 419 and 242) and
Italy (families 278, 747, and 786). In all cases, clinical
examination of the parents was normal, and no history
of neurological disease in the ascendants was reported.
All patients presented a severe spastic paralysis with
an infantile onset and a stereotyped ascending progres-
sion leading to tetraplegia and anarthria during the early
teenage years. All were considered normal at birth, and
spastic paraplegia started approximately at the age of
walking achievement. Weakness and spasticity, with
signs of pyramidal tract involvement, extended to the
upper limbs at age ∼7–10 years. All the patients were
wheelchair-bound by the age of 10 years. In the second
decade, the disease progressed to tetraplegia, anarthria,
dysphagia, and slow eye movements. Despite this very
early onset, long survival beyond the third and even
fourth decade was observed.
No other neurological or extraneurological clinical
features were noticed, and cognitive functions were
spared. Results of extensive studies, including a wide
range of metabolic studies, muscular biopsy, and elec-
tromyography (EMG) with sensory and motor
nerve–conduction velocities (NCV), were normal. Mo-
tor-evoked potentials (MEP) in all patients showed early
abolition of corticospinal responses, in contrast with
normal responses of the somatosensory-evoked poten-
tials (SSEP), which became abnormal only in the later
stages. Visual and auditory evoked potentials were also
normal. Brain MRI showed different degrees of abnor-
malities, extending from normal images in the youngest
patients to severe sylvian, brainstem, and spinal cord
atrophy with hyperlucencies in T2-weighted images
along the pyramidal tract in the oldest patients.
Genotyping
Informed consent was obtained from all families, in
accordance with local institutional review board guide-
lines. Genomic DNA from peripheral bloodwas extracted
with Nucleon BACC2 (Amersham). Forty-three poly-
morphic microsatellites were used for genotyping.
Twenty-eight microsatellites were in known HSP loci: 10
for autosomal recessive loci (8q11-12 [D8S285
and D8S260], 16q24.3 [D16S520, D16S413, and
D16S3023], 15q13 [D15S1007, D15S971, and
D15S1012], and 3q27-28 [D3S1294 and D3S2747]) and
18 for autosomal dominant loci (2p21 [D2S367], 14q13-
21 [D14S288 and D14S276], 15pter-q14 [D15S128,
D15S1002, and D15S165], 8q23-24 [D8S514 and
D8S284], 19q13 [D19S220, D19S420, and D19S902],
12q13 [D12S368, D12S1586, and D12S83], 2q24
[D2S117], and 10q23.3-24.2 [D10S192, D10S1709, and
D10S1686]). Fifteen microsatellites were located in and
around the ALS2 locus on chromosome 2q33-35:
D2S117, D2S115, D2S116, D2S309, D2S2309,
D2S2214, D2S346, D2S2289, D2S72, D2S307,
D2S2189, D2S2237, D2S155, D2S325, and D2S2382.
PCR amplification and electrophoresis.—Primers for
polymorphic markers D8S285, D8S260, D16S520,
D15S1007, D15S1012, D2S367, D14S288, D14S276,
D15S128, D15S1002, D15S165, D8S514, D8S284,
Figure 1 Pedigree and haplotype analysis of 10 families with the IAHSP phenotype. Individuals from 10 families were genotyped with
15 markers of the 2q33-34 region, including the markers of the ALS2 critical region (D2S116, D2S2309, D2S2214, D2S346, D2S2289, D2S72,
D2S307, D2S2189, and D2S2237). Haplotypes were generated under the assumption that the smallest number of recombination events was
present. Haplotype analysis defined the boundary of the IAHSP locus within the ALS2 critical region, between markers D2S116 and D2S2237.
For ALS2, a plus sign () denotes the mutated allele and a minus sign () the nonmutated allele. Asterisks (*) denote families with an ALS2
mutation.
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Table 1
Summary of Clinical and MRI Data for 15 Patients with AIHSP
Family
and
Patient
Country
of Origin Sex
Age
(years)
Age at
Onset
(years)
Loss of
Walking
(years)a
Upper-Limb
Involvment
(years)
Bulbar
Involvement
(years)
Alsin
Mutation
Found
362: Algeria
2 M 36 1 NA !7 13 Yes
3 F 31 1 NA !7 13 Yes
5 M 24 1 NA !7 13 Yes
279: Italy
1 M 14 1.2 1.5 9 10 No
2 M 10 1 10 7 10 No
408: Libya
1 M 8 1.5 8 No No No
2 M 16 1 10 No 15 No
419-1 France F 18 1.5 4 6 8 Yes
283-1 Italy F 23 1.4 5 10 12 Yes
278-1 Italy M 20 1.5 4 9 13 Yes
242-2 France M 18 5 9 13 16 No
751: Italy
1 M 11 1.5 NA 7 10 No
2 F 4 2 No No No No
747-2 Italy F 20 1 4 10 11 No
786-2 Italy F 7 3 4 No No No
a NA p not achieved.
D19S220, D19S420, D19S902, D12S368, D12S83,
D10S192, D2S117, D2S325, and D2S2382 were ob-
tained from the ABI Linkage Mapping Set version 2
(LMS2; Applied Biosystems) and were used according
to the conditions recommended by the manufacturer.
Primer sequences of the remaining 15 markers—
D2S116, D2S115, D2S2309, D2S2214, D2S309,
D2S307, D2S346, D2S2289, D2S72, D2S2189,
D2S2237, D2S155, D16S413, D16S3023, D15S971,
D3S1294, D3S2747, D12S1586, and D10S1709—were
available from the Ge´ne´thon microsatellite linkage map.
PCR reactions and thermocycling conditions were iden-
tical to those used for markers from the LMS2 marker
set. PCR products were electrophoresed on a 4.25%
denaturing polyacrylamide gel, using an ABI 377 se-
quencer. They were sized by the Genescan program, ver-
sion 2.1, and scored by the Genotyper 2.0 program.
Linkage analysis.—Linkage analyses were performed
on a Sun station, using the facilities provided by the
INFOBIOGEN support. The LINKAGE package [La-
throp et al. 1985], version 5.1, was used for the gen-
eration of pedigree files (MAKEPED) and data files
(PREPLINK), using the allele frequency of each marker
as found in the CEPH database.
Two-point LOD scores were calculated by MLINK,
under the assumption of recessive inheritancewith a pen-
etrance of 90%. Recombination frequencies were as-
sumed to be equal between males and females.
Multipoint LOD scores were calculated for 15 mark-
ers on chromosome 2q33-35 with GENEHUNTER, ver-
sion 2.0, assuming a recessive mode of inheritance, ge-
netic homogeneity, and a penetrance of 90%. Allele
frequencies of each marker were those of the CEPH da-
tabase. The order of markers and their respective dis-
tances were obtained from linkage maps from the Ge´-
ne´thon microsatellite linkage map and the Marshfield
Center for Medical Genetics and from the physical map
of the ALS2 critical region on human chromosome
2q33-34 (Hadano et al. 1999), as follows: D2S117–1.2
cM–D2S115–3 cM–D2S116–0.1 cM–D2S309–0.1 cM–
D2S2309–0.1 cM–D2S2214–0.1 cM–D2S346–0.53
cM–D2S2289–0.1 cM–D2S72–0.53 cM–D2S307–0.1
cM–D2S2189–1.25 cM–D2S2237–2.49 cM–D2S155–
1.61 cM–D2S325–8.96 cM–D2S2382.
Mutation Detection
Total RNA was extracted from Epstein-Barr virus
(EBV)–transformed lymphoblasts from all affected pa-
tients, with RNA Now (Biogentex). First-strand cDNA
synthesis with an oligo-dT primer (Superscript Pream-
plification system [Invitrogen]) was followed by PCR
amplification with the 17 primers listed in table 2, which
cover the short as well as the long ALS2 cDNA. After
35 cycles of PCR amplification, we purified the PCR
products, using a QIAquick PCR purification kit (Qia-
gen). We sequenced both strands of PCR products, using
the Big DyeDeoxy Terminator Cycle Sequencing kit (Per-
kin Elmer) on an ABI 377 automatic sequencer (Applied
Biosystems).
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Table 2
Sequences of Primers for PCR and ALS2 cDNA Sequencing
PRIMER
SET
NAME
PRIMER (5′r3′)
PRODUCT
SIZE
(BP)Forward Reverse
ALS2-1 ATGATTTGGTGATGG GACAGGATTTGGTTC 428
ALS2-2 GGAGCAGTGACAGAC CCTAATGGGCAACAA 455
ALS2-3 CAATGCCTCCCTTCC ATGGTATGTTTCTGG 346
ALS2-4 GCAGGAAGAAGTATT AAAACAAGCCCAACA 481
ALS2-5 GTCCTCTCAACAAAA TCTGCTTCTCCACTG 585
ALS2-6 AGGCAGGCAGTAGTG TGGGATTTCGCAGTA 418
ALS2-7 CTGACCCCACATAC TCCACCAAGGCTAAA 515
ALS2-8 CCCAGGTTTACTCAT CAATGGCAGGCTTAG 672
ALS2-9 ACAACCTTCCAGAGA GCTTCCTTCCTTTT 712
ALS2-10 AAGATTTGTCAGAAG TGGTGCGTGGAGAA 391
ALS2-11 GTCTTGCTCTCCATC CCATACCCATCTTCC 610
ALS2-12 TCACTCTCATTTCAT TTCTTATCCATTACC 517
ALS2-13 TTGGAAGATGGGTAT TAGGTTTGAAGTAGG 547
ALS2-14 GAATGTGGCAAGATG TCAGGAAATAAGAAC 751
ALS2-15 TCACTGGAACCTACT GCATAAAGCATAAAC 691
ALS2-16 CTGGTGAGGTTCTTA GCATCTTTCGTGGTT 362
ALS2-17 GCTGTTTATGCTTTA GCTCTTATTATTGGT 649
When mutations were detected, the corresponding ex-
ons were amplified from genomic DNA of all family
members, using the primers and conditions proposed by
Hadano et al. (2001a). Sequencing conditions were iden-
tical to those used in the cDNA analysis.
Results
Linkage and Haplotype Analysis
Genotyping for the 12 recessive and dominant HSP
loci reported was performed in seven families (families
362, 279, 408, 419, 283, 278, and 242). These loci were
excluded by a two-point LOD score 0 for all families
and by haplotype analysis, which showed recombinant
events (data not shown). Using 11 markers (D2S117,
D2S116, D2S309, D2S346, D2S2289, D2S307,
D2S2189, D2S2237, D2S155, D2S325, and D2S2382)
in and around the ALS2 locus, we found a maximum
two-point LOD score of 2.86 at recombination fraction
(v) 0 for the marker D2S309 and a maximummultipoint
LOD score of 3.15 between the markers D2S116 and
D2S325 (data not shown). Therefore, we genotyped the
45 individuals from the 10 affected families with a total
of 15 markers, including the ALS2 critical region. We
obtained a maximum two-point LOD score of 5.87 at
for the marker D2S309 and a maximum multi-vp 0
point LOD score of 6.66 between the markers D2S116
and D2S2237 (fig. 2). Haplotype analysis (fig. 1) dem-
onstrated no recombinant event in the region between
the markers D2S116 and D2S2237. In addition, the af-
fected patients from the first-degree consanguineous
families (families 362 and 283) were homozygous for
markers between D2S309 and D2S346, including the
ALS2 critical region. These results established that
IAHSP is linked to the 2q33-35 region in an interval
including the ALS2 critical region.
Mutation Detection
The minimal chromosomal region identified in our
families is enriched in transcripts particularly expressed
in the motor nervous system (Hadano et al. 2001b). To
test whether IAHSP is allelic to ALS2 at the ALS2 gene
locus, we sequenced the alsin cDNA from EBV-trans-
formed lymphoblasts from one affected patient in each
family.
We detected four mutations (in families 362, 419, 283,
and 278): three deletions and one splice-site mutation.
All the mutations lead to abnormal short and long ALS2
transcripts and truncated alsin proteins (fig. 3).
In family 362, a single–base pair deletion (3742delA)
was detected in exon 22 of the long ALS2 transcript,
leading to a stop codon at the 1206 aa position. The
three affected patients (patients 2, 3, and 5) were ho-
mozygous for the deletion, whereas both parents and
one unaffected sibling were heterozygous and an unaf-
fected sibling was homozygous for the wild-type allele
(fig. 1).
In family 419, a homozygous 10-bp deletion
(1471delGTTTCCCCCA) was detected in exon 6 of the
long ALS2 transcript. This deletion leads to a frameshift
(V491r) and a premature stop codon at the 493 aa
position. Genomic DNA analysis with primers ampli-
fying exon 6 and the corresponding splice-site regions
demonstrated a homozygous point mutation (GrT) in
the consensus CAG-acceptor splice site of exon 6. Both
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Figure 2 Multipoint LOD scores for the ALS2 locus. Markers used, with their distance (in cM), are plotted against multipoint LOD
scores. A maximum multipoint LOD score of 6.66 was obtained between the markers D2S116 and D2S2237. The grey bar represents the
IAHSP locus, and the black bar represents the ALS2 locus. These loci can be superposed to uncover a region between markers D2S116 and
D2S2237.
parents and one unaffected sibling were heterozygous
for the mutation (fig. 1).
In family 283, a 2-bp deletion (2660del AT) was de-
tected in exon 13 of the long ALS2 transcript. This de-
letion leads to a frameshift (N845r), and a premature
stop codon 12 codons after the deletion site at the 858
aa position. Genomic DNA analysis of exon 13 dem-
onstrated that the affected patient was homozygous for
this deletion and that her parents were heterozygotes,
whereas the unaffected brother was homozygous for the
normal allele (fig. 1).
In family 278, a homozygous 2-bp deletion (1130
delAT) was detected in exon 4 of both the short and the
long ALS2 transcripts. The deletion leads to a frameshift
(I331r) and a premature translation termination at the
335 aa position. Genomic DNA analysis of exon 4 dem-
onstrated that both parents and the unaffected sibling
were heterozygous for the deletion (fig. 1). In the six
remaining families (families 279, 408, 242, 751, 747,
and 786), no abnormalities were detected by amplifi-
cation and sequencing of the entire alsin cDNA.
Linkage Analysis in Families without Mutations
Two-point and multipoint LOD scores obtained with
the 10 markers of the ALS2 critical region for the six
families without mutations were compared with those
obtained for the four families with alsin mutations. We
found a maximum two-point LOD score of 2.02 at
for the marker D2S2289. The two markers flank-vp 0
ing the ALS2 gene have maximum two-point LOD
scores of 1.84 for D2S309 and 0.32 for DS2309 at
(table 3). A maximum multipoint LOD score ofvp 0
2.42 between the markers D2S116 and D2S2237 was
observed.
Discussion
We demonstrated alsin mutations in IAHSP, suggesting
that IAHSP is allelic to juvenile ALS and JPLS. IAHSP
can be distinguished from those two disorders by the
association of (1) an infantile onset, at the age of walking
achievement, with an ascending progression during
childhood but a long survival during adulthood; (2) ab-
Figure 3 Electrophoregram results of alsin cDNA sequencing obtained from RT-PCR with RNA extracted from EBV-transformed lym-
phoblasts of one affected patient from each of the following families: 362, 419, 283, and 278. Three homozygous deletions (in families 362,
283, and 278) were found. All resulted in truncated alsin proteins, involving the short variant only in family 278. For family 419, cDNA
analysis demonstrated a 12-bp deletion in the long ALS2 transcript, leading to a truncated long alsin protein. Genomic DNA analysis of the
affected patient demonstrated a homozygous point mutation (GrT) in the consensus acceptor splice site (CAG) of exon 6.
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Table 3
Two-point LOD Scores at the Maximum-Likelihood Estimate (Zmax)
of v between IAHSP and Polymorphic Markers of the ALS2 Locus
LOCUS
FAMILIES
WITHOUT
MUTATIONS
(n p 6)
FAMILIES
WITH
MUTATIONS
(n p 4) TOTAL
Zmax v Zmax v Zmax v
D2S116 1.30 .00 3.82 .00 5.12 .00
D2S309a 1.84 .00 4.03 .00 5.87 .00
D2S2309 0.32 .00 2.86 .00 3.18 .00
D2S2214 0.34 .00 3.06 .00 3.40 .00
D2S346 1.84 .00 1.52 .00 3.36 .00
D2S2289 2.02 .00 3.11 .00 5.13 .00
D2S72 1.84 .00 2.92 .00 4.76 .00
D2S307 1.54 .00 2.94 .00 4.48 .00
D2S2189 1.64 .00 3.51 .00 5.15 .00
D2S2237 1.84 .00 3.61 .00 5.45 .00
a Position of the ALS2 gene.
sence or severe delay of MEP, contrasting with normal
SSEP, EMG, and peripheral NCVs; and (3) a progressive
atrophy of the pyramidal tracts apparent on MRI after
120 years of evolution, which suggests a primitive, early
degeneration of the upper motor neurons.
The different geographic origins of our families dem-
onstrate that alsin mutations are not restricted to con-
sanguineous Arabic families. The common Mediterra-
nean origin of the three families with mutations we
studied and of other reported families with mutations
suggests that alsin mutations are more frequent in this
region than was initially thought.
Analyzing ALS2 cDNA obtained from lymphoblas-
toid cell lines, we found four different mutations leading
to truncated gene products. However, we did not ob-
serve any straightforward genotype-phenotype corre-
lation. Mutations in either the short or the long form
of alsin, or in both forms, gave rise to similar pheno-
types and disease progression. For instance, in family
278 we detected a mutation that affected both the short
and the long alsin transcripts, despite the affected pa-
tient’s having displayed no signs of lower motor in-
volvement at the age of 24 years. This seems to argue
against the hypothesis that an intact short form of alsin
protects the lower motor neurons of the spinal cord and
brain stem from being affected (Hadano et al. 2001).
Short and long alsin transcripts are widely expressed in
the brain and spinal cord but also in other tissues out-
side the CNS (Hadano et al. 2001a), including the pe-
ripheral sensory nerve (E.E.-P., unpublished data). In
addition, only ∼50% of the patients in the Tunisian
family with ALS2 originally described showed dener-
vation on EMG analysis (Ben Hamida et al. 1990).
Thus, lower motor-neuron involvement does not relate
to mutations in the short alsin, as hypothesized else-
where (Yang et al. 2001). Our results suggest that alsin
mutations are responsible for a primitive retrograde de-
generation of the upper motor neurons of the pyramidal
tracts. In a subgroup of patients, additional unidentified
factors might contribute to lower motor-neuron in-
volvement. The large variability in the size of truncated
proteins does not correlate with the severity of the phe-
notype and suggests loss of function. Further studies at
the protein level, using alsin antibodies, are certainly
needed.
The function of alsin is still unknown, but several
homology domains, including RCC1 (guanine exchange
factor [GEF] of RanGTPase [RanGEF]), Db1-pleckstrin
(RhoGEF), VPS9 (GEF for GTPase Rab5 vacuolar pro-
tein-sorting 21 protein), and two MORN (membrane
occupation and recognition plexus) motifs have been
found. Alsin is unique in that it might exhibit different
potential GEF activities (GEFRho, GEFRan, and GEF-
Rab). GEFs are known to associate with the GDP-
bound form of GTPases and to accelerate GDP disso-
ciation and GTP binding, thereby activating the
GTPases. This suggests potential functions involving
regulation of microtubule assembly, signalling cascades,
neuronal morphogenesis, membrane transport or traf-
ficking, organization of the actin cytoskeleton, vacuolar
protein sorting, or endocytic trafficking (Hadano et al.
2001a; Yang et al. 2001). Alsin can play a key function
in neurons as a regulator of the balance between these
different GEFs.
Despite a relatively high LOD score without identi-
fiable genetic heterogeneity in the ALS2 genomic critical
region, in 6 of the 10 families with IAHSP, no alsin
mutations were found by sequence analysis of illegiti-
mate alsin transcripts amplified by RT-PCR from total
RNA extracts of lymphoblastoid cell lines. Further anal-
yses are needed to rule out mutations in the intronic
and regulatory regions of theALS2 gene. Quantification
of alsin transcripts from tissues with a constitutive ex-
pression of the ALS2 gene, easy to collect as peripheral
nerve biopsy specimens in affected patients, would be
of great interest. An alternative hypothesis would be the
presence of a true genetic heterogeneity in IAHSP. Such
genetic heterogeneity exists in JPLS; one family with a
recombinant event within the ALS2 critical region has
been described elsewhere (Yang and al. 2001). In our
group of families with IAHSP without identified alsin
mutations, no recombination was observed. Surpris-
ingly, however, affected individuals of family 408 are
not homozygous for the haplotype cosegregating with
the ALS2 locus, despite both parents’ having come from
the same Libyan tribe, with a high degree of consan-
guinity. A nonsignificant maximum LOD score of 2.02
was obtained for D2S2289, a marker at a 0.5-cM dis-
tance from the ALS2 gene in the ALS2 critical region.
Involvement of an another nearby gene in this critical
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region, rich in transcripts expressed in the motor nerv-
ous system (Hadano et al. 2001), cannot be excluded.
We show that mutations in alsin are associated with
a subset of the IAHSP phenotype. Thus, alsin mutation
is responsible for a primitive, retrograde degeneration
of the upper motor neurons of the pyramidal tract, lead-
ing to a clinical continuum from infantile (IAHSP) to
juvenile forms with (ALS2) or without (JPLS) lower
motor-neuron involvement. Further analyses will deter-
mine whether other hereditary disorders characterized
by primary degeneration of the central motor pathways,
such as pure forms of spastic paraplegia, could be the
result of alsin dysfunction.
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